About Exicure, Inc.
https://www.exicuretx.comExicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain.
CEO
Andy Yoo
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2024-08-28 | Reverse | 1:5 |
| 2022-06-30 | Reverse | 1:30 |
ETFs Holding This Stock
Summary
Showing Top 2 of 2
Ratings Snapshot
Rating : C
Price Target
Institutional Ownership
BROADFIN CAPITAL, LLC
Shares:2.71M
Value:$16.25M
ABINGWORTH LLP
Shares:281.64K
Value:$1.69M
CARLYLE GROUP INC.
Shares:281.64K
Value:$1.69M
Summary
Showing Top 3 of 21
About Exicure, Inc.
https://www.exicuretx.comExicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $2.39M ▼ | $-2.44M ▲ | 0% | $-0.39 ▲ | $-2.37M ▼ |
| Q2-2025 | $0 | $2.51M ▲ | $-2.62M ▼ | 0% | $-0.41 ▼ | $-2.32M ▲ |
| Q1-2025 | $0 | $-2.95M ▼ | $3.01M ▲ | 0% | $0.49 ▲ | $-2.92M ▲ |
| Q4-2024 | $0 | $7.59M ▲ | $-7.18M ▼ | 0% | $-1.19 ▼ | $-6.97M ▼ |
| Q3-2024 | $0 | $2.57M | $-1.09M | 0% | $-0.15 | $-863K |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $4.44M ▼ | $15.27M ▼ | $8.34M ▼ | $6.93M ▼ |
| Q2-2025 | $7.86M ▼ | $18.74M ▼ | $9.88M ▲ | $8.86M ▼ |
| Q1-2025 | $10.42M ▼ | $20.68M ▲ | $9.3M ▲ | $11.38M ▲ |
| Q4-2024 | $12.51M ▲ | $15.06M ▲ | $8.28M ▼ | $6.77M ▲ |
| Q3-2024 | $343K | $10.63M | $9.09M | $1.54M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-2.44M ▲ | $0 ▲ | $0 ▲ | $0 | $-3.42M ▼ | $0 ▲ |
| Q2-2025 | $-2.62M ▼ | $-2.28M ▼ | $-280K ▲ | $0 ▼ | $-2.56M ▼ | $-2.6M ▼ |
| Q1-2025 | $3.01M ▲ | $-1.6M ▼ | $-2.09M ▼ | $1.6M ▼ | $-2.09M ▼ | $-1.6M ▼ |
| Q4-2024 | $-7.18M ▼ | $-845K ▼ | $0 | $12.4M ▲ | $11.56M ▲ | $-845K ▼ |
| Q3-2024 | $-1.09M | $-449K | $0 | $0 | $-185K | $-449K |
CEO
Andy Yoo
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2024-08-28 | Reverse | 1:5 |
| 2022-06-30 | Reverse | 1:30 |
ETFs Holding This Stock
Summary
Showing Top 2 of 2
Ratings Snapshot
Rating : C
Price Target
Institutional Ownership
BROADFIN CAPITAL, LLC
Shares:2.71M
Value:$16.25M
ABINGWORTH LLP
Shares:281.64K
Value:$1.69M
CARLYLE GROUP INC.
Shares:281.64K
Value:$1.69M
Summary
Showing Top 3 of 21